Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis
Main finding · SU changeResult — go to the resultAdjusted SU change difference −1.8 mg/dL CI −2.7 to −0.9Authors' conclusion
Among patients with gout, SGLT2i was associated with a notable reduction in SU compared with sulfonylurea, with a larger reduction among patients without diabetes.
Study context
- Population
- Patients with gout and baseline serum urate (SU) >6 mg/dL with SU measured within 90 days before and after SGLT2i or sulfonylurea initiation
- Participants
- 28 vs 28
- Exposure
- SGLT2i initiation vs sulfonylurea initiation
- SGLT2in = 28
- Sulfonylurean = 28reference
- Outcome
- SU change after initiation
Methodological detailscomparative effectiveness, multivariable linear regression
- Comparative effectiveness
- Multivariable linear regression
Main finding
SU change
Adjusted SU change difference
−1.8 mg/dL
CI −2.7 to −0.9
Change by group
SGLT2i
−1.8
mean · 95% CI −2.4–-1.1 · mg/dL
Sulfonylurea
+0.3
CI −0.3–1.0 · mg/dL
SGLT2ivs Sulfonylurea
adjusted SU change difference −1.8 mg/dL (CI −2.7 to −0.9)
As reported in the abstract
Observational data: associations, not effects.
Further findings
mg/dL
| Outcome | SGLT2i with diabetes | SGLT2i without diabetes | Adjusted difference (mg/dL) (CI) | |
|---|---|---|---|---|
| SU change among SGLT2i initiators, withvs without diabetes (subgroup) | −1.2 (CI −1.8–-0.6) | −2.5 (CI −3.6–-1.3) | −1.4 (−2.4 to −0.5) | |
| −3−2−101Difference, mg/dL (linear scale) |
SU reduction by subgroup
- SU reduction persisted regardless of ULT or diuretic use and presence of diabetes, CKD or HF
Original publication
Serum urate change among gout patients treated with sodium-glucose cotransporter type 2 inhibitors vs. sulfonylurea: A comparative effectiveness analysis. Semin Arthritis Rheum. Published 5 April 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →